Nventa granted U.S. patent covering heat shock protein fusion to treat anogenital warts
Advertisement
Nventa Biopharmaceuticals Corporation announced that the U.S. Patent and Trademark Office has issued Patent Number 7,211,411 B2 to Nventa covering the use of HspE7, the Company's investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, to treat patients with anogenital warts. This new U.S. patent covers a method of treating a patient with anogenital warts using a fusion protein comprised of a heat shock protein from the Hsp60 family, which includes Hsp65, and an HPV (type 16) E7 antigen. This patent provides additional patent exclusivity for HspE7 to treat anogenital warts patients through September 2022.